Active, not recruitingPhase 3NCT06640530
Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin
Studying Germ cell tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Biocad
- Intervention
- BCD-263(drug)
- Enrollment
- 392 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2027
Study locations (30)
- Healthcare Institution "Brest Regional Oncological Dispensary", Brest, Belarus
- Health Institution "Gomel Regional Clinical Oncology Center", Homyel, Belarus
- Healthcare Institution "Minsk City Clinical Cancer Center", Minsk, Belarus
- State Institution "Republic Scientific and Practical Centre for Oncology and Medical Radiology Named after N.N.Aleksandrov", Minsk, Belarus
- Shaheed Zulfiqar Ali Bhutto Medical University, Islamabad, Pakistan
- Rehman Medical Institute, Peshawar, Pakistan
- Chelyabinsk Regional Clinical Center for Oncology and Nuclear Medicine, Chelyabinsk, Chelyabinsk Oblast, Russia
- Clinical Oncologic Dispensary No. 1, Krasnodar, Krasnodar Kari, Russia
- Krasnoyarsk Regional Clinical Oncological Dispensary named after A.I. Kryzhanovsky, Krasnoyarsk, Krasnoyarsk Krai, Russia
- JSC "Modern Medical Technologies", Saint Petersburg, Sankt-Peterburg, Russia
- Saint-Petersburg Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological), Saint Petersburg, Sankt-Peterburg, Russia
- State Budgetary Institution of Healthcare of the Arkhangelsk Region "Severodvinsk City Hospital №2 of Emergency", Arkhangelsk, Russia
- Regional State Budgetary Healthcare Institution "Altai Regional Oncological Dispensary", Barnaul, Russia
- Ivanovo Regional Oncology Center, Ivanovo, Russia
- State Health Care Institution "Republican Clinical Cancer Center," the Ministry of Health of the Udmurt Republic, Izhevsk, Russia
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06640530 on ClinicalTrials.govOther trials for Germ cell tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07552233NK Cell Therapy for Malignant Solid Brain TumorsPeking University Third Hospital
- RECRUITINGNCT07314164Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior TreatmentIpsen
- RECRUITINGPHASE1NCT07143812A Study to Evaluate the Safety of a Stem Cell-Based Gene and Cell Therapy in Patients With Newly Diagnosed GlioblastomaCHA University
- RECRUITINGNANCT06910306Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent GlioblastomaAlpha Tau Medical LTD.
- RECRUITINGNANCT07459101UNIty-Based MR-Linac Guided Adaptive RadioThErapy for High GraDe Glioma-4Sunnybrook Health Sciences Centre
- RECRUITINGPHASE1, PHASE2NCT07193966NG2 and DLL3 CAR-T Cells Targeting MelanomaShenzhen Geno-Immune Medical Institute
- RECRUITINGPHASE2NCT06712927Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain MetastasesStanford University
- RECRUITINGPHASE1, PHASE2NCT06712875MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric GliomasAnn & Robert H Lurie Children's Hospital of Chicago